113 related articles for article (PubMed ID: 17325855)
1. CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
Chang ST; Lu CL; Chuang SS
Leuk Lymphoma; 2007 Jan; 48(1):117-21. PubMed ID: 17325855
[TBL] [Abstract][Full Text] [Related]
2. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
4. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
5. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.
Geissinger E; Bonzheim I; Roth S; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Leuk Lymphoma; 2009 Jun; 50(6):1010-6. PubMed ID: 19479612
[TBL] [Abstract][Full Text] [Related]
6. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
7. CD52 expression in mantle cell lymphoma.
Bass AJ; Gong J; Nelson R; Rizzieri DA
Leuk Lymphoma; 2002 Feb; 43(2):339-42. PubMed ID: 11999566
[TBL] [Abstract][Full Text] [Related]
8. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
9. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.
Boulland ML; Meignin V; Leroy-Viard K; Copie-Bergman C; Brière J; Touitou R; Kanavaros P; Gaulard P
Am J Pathol; 1998 Oct; 153(4):1229-37. PubMed ID: 9777954
[TBL] [Abstract][Full Text] [Related]
10. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal T cell lymphoma: predominant cytotoxic phenotypes, including alpha/beta, gamma/delta T cell and natural killer cells.
Katoh A; Ohshima K; Kanda M; Haraoka S; Sugihara M; Suzumiya J; Kawasaki C; Shimazaki K; Ikeda S; Kikuchi M
Leuk Lymphoma; 2000 Sep; 39(1-2):97-111. PubMed ID: 10975388
[TBL] [Abstract][Full Text] [Related]
12. Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.
Ohshima K; Liu Q; Koga T; Suzumiya J; Kikuchi M
Virchows Arch; 2002 Apr; 440(4):425-35. PubMed ID: 11956825
[TBL] [Abstract][Full Text] [Related]
13. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.
Petit B; Leroy K; Kanavaros P; Boulland ML; Druet-Cabanac M; Haioun C; Bordessoule D; Gaulard P
Hum Pathol; 2001 Feb; 32(2):196-204. PubMed ID: 11230707
[TBL] [Abstract][Full Text] [Related]
14. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
Salisbury JR; Rapson NT; Codd JD; Rogers MV; Nethersell AB
J Clin Pathol; 1994 Apr; 47(4):313-7. PubMed ID: 8027367
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD52 in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
[TBL] [Abstract][Full Text] [Related]
17. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
Hertenstein B; Wagner B; Bunjes D; Duncker C; Raghavachar A; Arnold R; Heimpel H; Schrezenmeier H
Blood; 1995 Aug; 86(4):1487-92. PubMed ID: 7632956
[TBL] [Abstract][Full Text] [Related]
18. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
[TBL] [Abstract][Full Text] [Related]
19. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
20. T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute.
Lu D; Lin CN; Chuang SS; Hwang WS; Huang WT
Leuk Lymphoma; 2004 May; 45(5):923-8. PubMed ID: 15291350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
